PMID- 17869043
OWN - NLM
STAT- MEDLINE
DCOM- 20080430
LR  - 20181201
IS  - 0385-8146 (Print)
IS  - 0385-8146 (Linking)
VI  - 35
IP  - 1
DP  - 2008 Mar
TI  - Arsenic trioxide induced the apoptosis of laryngeal cancer via down-regulation of 
      survivin mRNA.
PG  - 95-101
AB  - OBJECTIVE: Arsenic trioxide (As(2)O(3)) is used clinically to treat acute 
      promyelocytic leukemia and has activity in vitro against several solid tumor cell 
      lines, where induction of differentiation and apoptosis are the prime effects. As 
      a novel anticancer agent for treatment of solid cancers, As(2)O(3) is promising 
      and the mechanism has been not still fully understood. Laryngeal squamous cell 
      carcinoma (LSCC) is one common tumor in head and neck cancers. The objective of 
      this study was to investigate the effects of As(2)O(3) on LSCC cell line HEP-2, 
      and their possible involvement in As(2)O(3)-induced apoptosis. METHODS: The cell 
      viability was analyzed by MTT assay method and the morphological changes were 
      observed by an inverted microscope and acridine orange (AO) staining. The 
      caspase-3 activity was measured by a fluorophotometer. The expression of survivin 
      mRNA was evaluated by RT-PCR. RESULTS: In this study, we demonstrated an 
      apoptotic effect of As(2)O(3) in LSCC cell line Hep-2. In Hep-2 cells, As(2)O(3) 
      decreased the cell viability, inhibited the growth and proliferation, induced 
      apoptosis and increased the activity of caspase-3 in a dose-dependent manner. And 
      the expression of survivin mRNA was also decreased in a dose-dependent manner. 
      CONCLUSION: We concluded that As(2)O(3) induced the apoptosis of Hep-2 cells via 
      down-regulating the expression of survivin mRNA.
FAU - Cheng, Baohua
AU  - Cheng B
AD  - Shandong University, Jinan, China.
FAU - Yang, Xinxin
AU  - Yang X
FAU - Han, Zaiwen
AU  - Han Z
FAU - An, Liangxiang
AU  - An L
FAU - Liu, Shuwei
AU  - Liu S
LA  - eng
PT  - Journal Article
DEP - 20070914
PL  - Netherlands
TA  - Auris Nasus Larynx
JT  - Auris, nasus, larynx
JID - 7708170
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oxides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Survivin)
RN  - EC 3.4.22.- (Caspase 3)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Arsenic Trioxide
MH  - Arsenicals/*pharmacology
MH  - Carcinoma, Squamous Cell/pathology
MH  - Caspase 3/analysis
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/*drug effects
MH  - Gene Expression/drug effects/genetics
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins
MH  - Laryngeal Neoplasms/pathology
MH  - Microscopy, Fluorescence
MH  - Microtubule-Associated Proteins/*genetics
MH  - Neoplasm Proteins/*genetics
MH  - Oxides/*pharmacology
MH  - RNA, Messenger/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survivin
MH  - Tumor Cells, Cultured/*drug effects/pathology
EDAT- 2007/09/18 09:00
MHDA- 2008/05/01 09:00
CRDT- 2007/09/18 09:00
PHST- 2007/03/02 00:00 [received]
PHST- 2007/07/27 00:00 [revised]
PHST- 2007/07/31 00:00 [accepted]
PHST- 2007/09/18 09:00 [pubmed]
PHST- 2008/05/01 09:00 [medline]
PHST- 2007/09/18 09:00 [entrez]
AID - S0385-8146(07)00132-0 [pii]
AID - 10.1016/j.anl.2007.07.009 [doi]
PST - ppublish
SO  - Auris Nasus Larynx. 2008 Mar;35(1):95-101. doi: 10.1016/j.anl.2007.07.009. Epub 
      2007 Sep 14.